International Journal Of Drug Regulatory Affairs
  • Year: 2026
  • Volume: 14
  • Issue: 1

Comprehensive Comparison of Clinical Trial Protocol & Clinical Investigation Plan in Different Countries

  • Author:
  • Chaitanya Sedamaki1, Hara Naga Ganesh Dhulipudi1, Rudra Vaishno1, D. Prasanthi1*
  • Total Page Count: 9
  • Page Number: 12 to 20

1Department of regulatory affairs, G. Pulla Reddy College of Pharmacy, Osmania University, Hyderabad, Telangana, India500028

*Corresponding author. E-mail address: prasanthidhanu@gmail.com (D. Prasanthi)

Abstract

Clinical research involving investigational medicinal products and medical devices is governed by region-specific regulatory frameworks that define the planning, review, and conduct of studies. The clinical trial protocol (CTP) and clinical investigation plan (CIP) serve as core regulatory documents required for approval and oversight. This review compares regulatory requirements for CTPs and CIPs in India, the United States, and the European Union, with a focus on definitions, structure, submission pathways, ethical considerations, and regulatory oversight. Across all regions, strong emphasis is placed on participant safety, scientific rationale, and compliance with good clinical practice. Common elements include study background, objectives, methodology, risk assessment, and data management. However, differences exist in terminology, approval processes, and region-specific expectations, particularly for medical device investigations and risk classification. Understanding both harmonised principles and jurisdiction-specific requirements can support regulatory compliance and facilitate efficient planning of multinational clinical research studies.

Despite differences in terminology, approval pathways, and regulatory authorities, a clear understanding of both global standards and region-specific requirements is essential for ensuring regulatory compliance and enabling efficient multinational clinical research.

Keywords

Clinical trial protocol, Clinical investigation plan, Regulatory requirements, Medical device regulation, CDSCO, FDA, European Union